IT IS IMPORTANT YOU CARRY THIS CARD WITH YOU AT ALL TIMES WHILE YOU ARE TAKING ELIQUIS®.

SHOW THIS CARD TO YOUR PHARMACIST, DENTIST AND OTHER HEALTHCARE PROFESSIONALS THAT TREAT YOU.

Patient Information

Name of patient

_____

Date of birth

_____

Please ask your doctor to complete this section.

Indication for anticoagulation

_____

Dosage of Eliquis®

_____

Contact details of prescribing physician

_____

Eliquis® (apixaban) Patient Alert Card

5 mg and 2.5 mg twice daily

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this card. You can also report side effects directly to the Medicines Authority at Post-licensing Directorate, 203, Level 3, Rue D'Argens, Gżira GŻR 1368, MALTA, webform at: www.medicinesauthority.gov.mt/adrportal or else to Pfizer Hellas Pharmacovigilance Department contact details: +30 210 67 85 908 and +30 210 67 85 808 (24-hour line),or their local representatives V.J Salomone Pharma Ltd. Tel. +356 21220174. By reporting side effects, you can help provide more information on the safety of this medicine

IT IS IMPORTANT YOU CARRY THIS CARD WITH YOU AT ALL TIMES WHILE YOU ARE TAKING ELIQUIS®.

SHOW THIS CARD TO YOUR PHARMACIST, DENTIST AND OTHER HEALTHCARE PROFESSIONALS THAT TREAT YOU.

Patient Information

Name of patient

_____

Date of birth

_____

Please ask your doctor to complete this section.

Indication for anticoagulation

_____

Dosage of Eliquis®

_____

Contact details of prescribing physician

_____

Eliquis® (apixaban) Patient Alert Card

5 mg and 2.5 mg twice daily

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this card. You can also report side effects directly to the Medicines Authority at Post-licensing Directorate, 203, Level 3, Rue D'Argens, Gżira GŻR 1368, MALTA, webform at: www.medicinesauthority.gov.mt/adrportal or else to Pfizer Hellas Pharmacovigilance Department contact details: +30 210 67 85 908 and +30 210 67 85 808 (24-hour line),or their local representatives V.J Salomone Pharma Ltd. Tel. +356 21220174. By reporting side effects, you can help provide more information on the safety of this medicine

Dear Patient,

You have been prescribed Eliquis® (apixaban) by your doctor. In order to use Eliquis® safely, please read the important information inside, as well as the Patient Information Leaflet provided with each pack of medicine.
Remember to take Eliquis® regularly as instructed and do not miss a dose.
Tell your doctor before you take this medicine if you are at an increased risk of bleeding.
Speak to your healthcare professional before taking any other medication.

Reporting side-effects
Patients are encouraged to report adverse drug reactions (ADRs) and medication errors with the use of medicinal products to their healthcare professionals.
Alternatively one can report to the Medicines Authority at Post-licensing Directorate, 203, Level 3, Rue D'Argens,Gżira GŻR 1368, MALTA, webform at:
www.medicinesauthority.gov.mt/adrportal
or else to Pfizer Hellas Pharmacovigilance Department contact details: +30 210 67 85 808 and +30 210 67 85 908 (24-hour line), or their local representatives V.J Salomone Pharma Ltd. Tel. +356 21220174.

Eliquis® Information for

PATIENTS

- Your doctor has prescribed Eliquis® to prevent clots
- Remember to take Eliquis® regularly as instructed. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule
- Do not stop taking Eliquis® without talking to your doctor, as you are at risk of suffering from a stroke or other complications due to blood clot formation
- Eliquis® prevents clots by helping to thin your blood. However, this may increase your risk of bleeding
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood or material that looks like coffee grounds, etc.
- In case of a bleeding event which does not stop on its own, **immediately seek medical attention**
- If you need a surgical or invasive procedure, inform the treating physician that you are taking Eliquis®

Eliquis® Information for

HEALTHCARE PROFESSIONALS

- Eliquis® (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa
- Eliquis® may increase the risk of bleeding. In case of major bleeding events, Eliquis® should be stopped immediately
- In case of surgical or other invasive procedure, Eliquis® needs to be stopped in advance (for details, see Summary of Product Characteristics)
- The prothrombin time (PT), INR and activated partial thromboplastin time (aPTT) clotting tests are not recommended to measure the anticoagulation effect of Eliquis®

Dear Patient,

You have been prescribed Eliquis® (apixaban) by your doctor. In order to use Eliquis® safely, please read the important information inside, as well as the Patient Information Leaflet provided with each pack of medicine.
Remember to take Eliquis® regularly as instructed and do not miss a dose.
Tell your doctor before you take this medicine if you are at an increased risk of bleeding.
Speak to your healthcare professional before taking any other medication.

Reporting side-effects
Patients are encouraged to report adverse drug reactions (ADRs) and medication errors with the use of medicinal products to their healthcare professionals.
Alternatively one can report to the Medicines Authority at Post-licensing Directorate, 203, Level 3, Rue D'Argens,Gżira GŻR 1368, MALTA, webform at:
www.medicinesauthority.gov.mt/adrportal
or else to Pfizer Hellas Pharmacovigilance Department contact details: +30 210 67 85 808 and +30 210 67 85 908 (24-hour line), or their local representatives V.J Salomone Pharma Ltd. Tel. +356 21220174.

Eliquis® Information for

PATIENTS

- Your doctor has prescribed Eliquis® to prevent clots
- Remember to take Eliquis® regularly as instructed. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule
- Do not stop taking Eliquis® without talking to your doctor, as you are at risk of suffering from a stroke or other complications due to blood clot formation
- Eliquis® prevents clots by helping to thin your blood. However, this may increase your risk of bleeding
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood or material that looks like coffee grounds, etc.
- In case of a bleeding event which does not stop on its own, **immediately seek medical attention**
- If you need a surgical or invasive procedure, inform the treating physician that you are taking Eliquis®

Eliquis® Information for

HEALTHCARE PROFESSIONALS

- Eliquis® (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa
- Eliquis® may increase the risk of bleeding. In case of major bleeding events, Eliquis® should be stopped immediately
- In case of surgical or other invasive procedure, Eliquis® needs to be stopped in advance (for details, see Summary of Product Characteristics)
- The prothrombin time (PT), INR and activated partial thromboplastin time (aPTT) clotting tests are not recommended to measure the anticoagulation effect of Eliquis®